. 2014 Jun 23;4(6):e119. doi: 10.1038/nutd.2014.15

Table 2. PK variables of MEM, TZP and CEF in the obese cohort, in those with a measured or estimated creatinine clearance greater than 80 ml min⁻¹ and data in non-obese patients found in the literature.

PK variables for each antibiotic	Obese cohort (N=56)	Obese cohort with CrCL_24h or CrCL_CG >80 ml min⁻¹ (N=36)	Non-obese patients [4,13–14,16,19–24]
MEM
VD (L)	48.0±25.1	54.6±23.6	12.5–17.8
VD (L)/kg	0.5±0.2	0.5±0.2	0.2
CL (L/H)	18.0±9.0	19.9±8.8	9.4–13.2
t_½ (H)	2.0±0.9	2.0±0.9	1.0

TZP
VD (L)	31.4±26.0	26.9±15.9	8.2–15.8
VD (L)/kg	0.3±0.3	0.2±0.1	0.2
CL (L/H)	8.9±4.7	13.1±10.4	8.0–14.5
t_½ (H)	2.2±1.8	1.5±1.4	0.6–1.1

CEF
VD (L)	33.9±27.7	42.9±31.6	14.3–19.3
VD (L)/kg	0.3±0.2	0.4±0.3	0.2
CL (L/H)	13.1±20.1	18.7±23.9	5.6–9.1
t_½ (H)	3.1±2.2	2.2±0.8	1.3–2.0

Abbreviations: CEF, cefepime/ceftazidime; CL, total body clearance; CrCL_24h, measured urinary creatinine clearance using 24-h urine collect; CrCL_CG, calculated creatinine clearance using the Cockcroft-Gault equation; MEM, meropenem; PK, pharmacokinetic; t_½: half-life; TZP, piperacillin-tazobactam; VD, volume of distribution.

Data for the obese cohort are expressed as mean values with standard deviations. Data for the non-obese patients are expressed in ranges of mean values found in the literature.

Table 2. PK variables of MEM, TZP and CEF in the obese cohort, in those with a measured or estimated creatinine clearance greater than 80 ml min−1 and data in non-obese patients found in the literature.

Table 2. PK variables of MEM, TZP and CEF in the obese cohort, in those with a measured or estimated creatinine clearance greater than 80 ml min⁻¹ and data in non-obese patients found in the literature.